Bhavesh Ashar Biography and Net Worth

Bhavesh Ashar joined SpringWorks Therapeutics in 2021. He has more than 20 years of global pharmaceutical and biotechnology experience, including significant experience in oncology. Previously, Bhavesh was Senior Vice President, General Manager of U.S. Oncology at Bayer Healthcare, where he served as Business Unit Head for the U.S. Oncology franchise and was responsible for a broad portfolio in prostate, liver, colorectal, GIST, hematologic and tumor-agnostic biomarker-driven cancers. Prior to joining Bayer in 2017, Bhavesh held roles of increasing responsibility at Sanofi Genzyme over a 15-year tenure, including Vice President, General Manager of U.S. Oncology and Vice President, Global Head of Transplant. Prior to Sanofi Genzyme, Bhavesh was a consultant with McKinsey & Company, where he served clients in the biopharmaceutical space. Bhavesh received a B.S. in mathematics from the Imperial College in London and an MBA from the University of Chicago.

What is Bhavesh Ashar's net worth?: The estimated net worth of Bhavesh Ashar is at least $2.43 million as of February 20th, 2025. Ashar owns 62,053 shares of SpringWorks Therapeutics stock worth more than $2,425,652 as of April 7th. This net worth evaluation does not reflect any other investments that Ashar may own. Additionally, Ashar receives a salary of $729,620.00 as Insider at SpringWorks Therapeutics. Learn More about Bhavesh Ashar's net worth.
How old is Bhavesh Ashar?: Ashar is currently 58 years old. There are 7 older executives and no younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics is Mr. Herschel S. Weinstein J.D., General Counsel & Secretary, who is 67 years old. Learn More on Bhavesh Ashar's age.
What is Bhavesh Ashar's salary?: As the Insider of SpringWorks Therapeutics, Inc., Ashar earns $729,620.00 per year. There are 4 executives that earn more than Ashar. The highest earning executive at SpringWorks Therapeutics is Mr. Saqib Islam J.D., CEO & Director, who commands a salary of $1,490,000.00 per year. Learn More on Bhavesh Ashar's salary.
How do I contact Bhavesh Ashar?: The corporate mailing address for Ashar and other SpringWorks Therapeutics executives is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. SpringWorks Therapeutics can also be reached via phone at 203-883-9490 and via email at investors@springworkstx.com. Learn More on Bhavesh Ashar's contact information.
Has Bhavesh Ashar been buying or selling shares of SpringWorks Therapeutics?: Bhavesh Ashar has not been actively trading shares of SpringWorks Therapeutics within the last three months. Most recently, Bhavesh Ashar sold 1,016 shares of the business's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $61.19, for a transaction totalling $62,169.04. Following the completion of the sale, the insider now directly owns 62,053 shares of the company's stock, valued at $3,797,023.07. Learn More on Bhavesh Ashar's trading history.
Who are SpringWorks Therapeutics' active insiders?: SpringWorks Therapeutics' insider roster includes Bhavesh Ashar (Insider), Badreddin Edris (COO), Julie Hambleton (Director), Saqib Islam (CEO), Daniel Lynch (Director), Daniel Pichl (Chief People Officer), L. Smith (Insider), and Stephen Squinto (Director). Learn More on SpringWorks Therapeutics' active insiders.
Are insiders buying or selling shares of SpringWorks Therapeutics?: In the last year, insiders at the sold shares 12 times. They sold a total of 460,766 shares worth more than $25,242,355.68. The most recent insider tranaction occured on March, 3rd when COO Badreddin Edris sold 20,000 shares worth more than $1,084,600.00. Insiders at SpringWorks Therapeutics own 7.6% of the company. Learn More about insider trades at SpringWorks Therapeutics.
Information on this page was last updated on 3/3/2025.

Bhavesh Ashar Insider Trading History at SpringWorks Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/20/2025	Sell	1,016	$61.19	$62,169.04	62,053

Bhavesh Ashar Buying and Selling Activity at SpringWorks Therapeutics

SpringWorks Therapeutics Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $37.57

$35.72

$39.90

50 Day Range

MA: $48.71

$35.82

$59.93

2 Week Range

Now: $37.57

$28.21

$62.00

Volume

1,583,279 shs

Average Volume

1,340,140 shs

Market Capitalization

$2.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Bhavesh Ashar Biography and Net Worth

What is Bhavesh Ashar's net worth?

How old is Bhavesh Ashar?

What is Bhavesh Ashar's salary?

How do I contact Bhavesh Ashar?

Has Bhavesh Ashar been buying or selling shares of SpringWorks Therapeutics?

Who are SpringWorks Therapeutics' active insiders?

Are insiders buying or selling shares of SpringWorks Therapeutics?